The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review
Background: Administration of convalescent plasma, serum, or hyperimmune immunoglobulin may be of clinical benefit for treatment of severe acute respiratory infections (SARIs) of viral etiology. We conducted a systematic review and exploratory meta-analysis to assess the overall evidence. Method...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
Oxford University Press
2014
|
| Subjects: | |
| Online Access: | https://eprints.nottingham.ac.uk/37680/ |
| _version_ | 1848795510689759232 |
|---|---|
| author | Mair-Jenkins, John Saavedra-Campos, Maria Baillie, J. Kenneth Cleary, Paul Khaw, Fu-Meng Lim, Wei Shen Makki, Sophia Rooney, Kevin D Beck, Charles R. Nguyen-Van-Tam, Jonathan S. |
| author_facet | Mair-Jenkins, John Saavedra-Campos, Maria Baillie, J. Kenneth Cleary, Paul Khaw, Fu-Meng Lim, Wei Shen Makki, Sophia Rooney, Kevin D Beck, Charles R. Nguyen-Van-Tam, Jonathan S. |
| author_sort | Mair-Jenkins, John |
| building | Nottingham Research Data Repository |
| collection | Online Access |
| description | Background: Administration of convalescent plasma, serum, or hyperimmune immunoglobulin may be of clinical benefit for treatment of severe acute respiratory infections (SARIs) of viral etiology. We conducted a systematic review and exploratory meta-analysis to assess the overall evidence.
Methods: Healthcare databases and sources of grey literature were searched in July 2013. All records were screened against the protocol eligibility criteria, using a 3-stage process. Data extraction and risk of bias assessments were undertaken.
Results: We identified 32 studies of SARS coronavirus infection and severe influenza. Narrative analyses revealed consistent evidence for a reduction in mortality, especially when convalescent plasma is administered early after symptom onset. Exploratory post hoc meta-analysis showed a statistically significant reduction in the pooled odds of mortality following treatment, compared with placebo or no therapy (odds ratio, 0.25; 95% confidence interval, .14–.45; I(2) = 0%). Studies were commonly of low or very low quality, lacked control groups, and at moderate or high risk of bias. Sources of clinical and methodological heterogeneity were identified.
Conclusions: Convalescent plasma may reduce mortality and appears safe. This therapy should be studied within the context of a well-designed clinical trial or other formal evaluation, including for treatment of Middle East respiratory syndrome coronavirus CoV infection. |
| first_indexed | 2025-11-14T19:33:14Z |
| format | Article |
| id | nottingham-37680 |
| institution | University of Nottingham Malaysia Campus |
| institution_category | Local University |
| last_indexed | 2025-11-14T19:33:14Z |
| publishDate | 2014 |
| publisher | Oxford University Press |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | nottingham-376802020-05-04T16:50:55Z https://eprints.nottingham.ac.uk/37680/ The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review Mair-Jenkins, John Saavedra-Campos, Maria Baillie, J. Kenneth Cleary, Paul Khaw, Fu-Meng Lim, Wei Shen Makki, Sophia Rooney, Kevin D Beck, Charles R. Nguyen-Van-Tam, Jonathan S. Background: Administration of convalescent plasma, serum, or hyperimmune immunoglobulin may be of clinical benefit for treatment of severe acute respiratory infections (SARIs) of viral etiology. We conducted a systematic review and exploratory meta-analysis to assess the overall evidence. Methods: Healthcare databases and sources of grey literature were searched in July 2013. All records were screened against the protocol eligibility criteria, using a 3-stage process. Data extraction and risk of bias assessments were undertaken. Results: We identified 32 studies of SARS coronavirus infection and severe influenza. Narrative analyses revealed consistent evidence for a reduction in mortality, especially when convalescent plasma is administered early after symptom onset. Exploratory post hoc meta-analysis showed a statistically significant reduction in the pooled odds of mortality following treatment, compared with placebo or no therapy (odds ratio, 0.25; 95% confidence interval, .14–.45; I(2) = 0%). Studies were commonly of low or very low quality, lacked control groups, and at moderate or high risk of bias. Sources of clinical and methodological heterogeneity were identified. Conclusions: Convalescent plasma may reduce mortality and appears safe. This therapy should be studied within the context of a well-designed clinical trial or other formal evaluation, including for treatment of Middle East respiratory syndrome coronavirus CoV infection. Oxford University Press 2014-07-16 Article PeerReviewed Mair-Jenkins, John, Saavedra-Campos, Maria, Baillie, J. Kenneth, Cleary, Paul, Khaw, Fu-Meng, Lim, Wei Shen, Makki, Sophia, Rooney, Kevin D, Beck, Charles R. and Nguyen-Van-Tam, Jonathan S. (2014) The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review. Journal of Infectious Diseases, 211 (1). pp. 80-90. ISSN 1537-6613 MERS coronavirus; convalescent plasma; severe acute respiratory infection; systematic review; meta-analysis http://jid.oxfordjournals.org/content/211/1/80 doi:10.1093/infdis/jiu396 doi:10.1093/infdis/jiu396 |
| spellingShingle | MERS coronavirus; convalescent plasma; severe acute respiratory infection; systematic review; meta-analysis Mair-Jenkins, John Saavedra-Campos, Maria Baillie, J. Kenneth Cleary, Paul Khaw, Fu-Meng Lim, Wei Shen Makki, Sophia Rooney, Kevin D Beck, Charles R. Nguyen-Van-Tam, Jonathan S. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review |
| title | The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review |
| title_full | The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review |
| title_fullStr | The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review |
| title_full_unstemmed | The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review |
| title_short | The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review |
| title_sort | effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review |
| topic | MERS coronavirus; convalescent plasma; severe acute respiratory infection; systematic review; meta-analysis |
| url | https://eprints.nottingham.ac.uk/37680/ https://eprints.nottingham.ac.uk/37680/ https://eprints.nottingham.ac.uk/37680/ |